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Please cite this article in press as: S.A. Bustin, JColorectal cancer (CRC) develops and progresses through a systematic selection for (epi) genetic altera-
tions that drive the transformation from normal colon epithelium to adenocarcinoma. These changes
affect both noncoding RNAs and mRNAs and so deﬁne the clinical behaviour of cancer cells within a dis-
tinctive host genetic and environmental context. Although earlier diagnosis and more effective treatment
modalities have decreased mortality from CRC, prognostic stratiﬁcation and adjuvant therapy selection
after surgery remain dependent on broad descriptive classiﬁcations, opportune histological markers of
poor prognosis and chemotherapy efﬁcacy data derived from diverse CRC populations. Crucially, there
is signiﬁcant inter- and intra-individual variability in response to, and tolerance of, chemotherapy treat-
ments. These limitations explain the small clinical beneﬁt of new agents studied in contemporary phase
III trials.
Molecular assays have the potential to address these constraints and there has been intense interest in
the identiﬁcation of clinically relevant molecular biomarkers. These must be easy to obtain and quantify
and ideally represent steps in well-understood carcinogenic pathways or host-response mechanisms.
Although some biomarkers can provide broad prognostic information based on CRC subtype (e.g. MSI sta-
tus) or can somewhat predict response to targeted therapies (e.g. KRAS), no RNA-based biomarkers have
entered routine clinical practice. This is due, in part, to the genetic heterogeneity of both patients and
CRC. In addition, serious underlying issues with regards to study design, poor technical protocols, inad-
equate quality controls and inappropriate data analysis prevent successful translation of research results.
Consequently, the identiﬁcation of clinically relevant panels of biomarkers will depend not just on further
advances in our understanding of CRC biology, but will need to be coupled with appropriate study designs
and more suitable, standardised and transparent techniques.
















Complete surgical excision of a primary tumour is the only cure
for early colorectal cancer (CRC) [1]. Appropriate post-operative
CRC patient management critically depends on accurate informa-
tion on the extent of tumour spread. Local extent of disease and
metastasis to regional lymph nodes (LNs) constitute the basis for
histopathological staging, which takes into account different de-
grees of penetration of the primary tumour through the bowel wall
(T), the degree of LN involvement (N) and the absence or presence
of distant metastasis (M) [2]. The American Joint Committee on
Cancer (AJCC) has condensed the TNM system into four stages,
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. Murphy, Methods (2012), httpmetastatic stage IV disease (Fig. 1). TNM staging has been aug-
mented by the residual tumour (R) classiﬁcation, which describes
the absence or presence of demonstrable residual tumour after
surgery and distinguishes between potentially curative resections
and primarily palliative surgical interventions: complete removal
of the tumour (R0), microscopic (R1) or macroscopic (R2) residual
disease.
Whilst histological indicators of cellular morphology have been
the mainstay of diagnostic and prognostic assessment of CRC and
are useful in providing information about tumour differentiation,
aggressiveness, and risk of recurrence, they are limited in their
ability to predict individual differences in clinical outcomes. For
example, JCC stage II CRCs are made up of tumours with consider-
able heterogeneity, which results in a pathological spectrum with
different 5-year disease free survival rates. This leads to inaccurate
prognostication for individual patients and clinical understaging of
approximately one third of stage II patients [3]. Hence a subgroup
of patients with presumed early CRC harbours a minimal, but clin-
ically signiﬁcant amount of occult disease that is currently unde-













































































Fig. 1. CRC stages. Only some of the possible permutations are shown for stages II and III. Stage I: Cancer has spread from the mucosa of the colon wall to the muscle layer. No
lymph node (LN) involvement. Stage II: Cancer has spread through the muscle layer of the colon wall to the serosa (IIA), through the serosa but not to nearby organs (IIB) or
through the serosa to nearby organs (IIC). No lymph node (LN) involvement. Stage III: Cancer may have spread through the mucosa of the colon wall to the submucosa and
muscle layer, and has spread to one to three nearby lymph nodes or tissues near the lymph nodes (IIIA), through the serosa but not to nearby organs (IIIB) or through the
serosa to nearby organs and to one or more nearby lymph nodes or to tissues near the lymph nodes. Stage IV: The cancer may or may not have grown through the wall of the
colon or rectum and has spread through the blood and lymph nodes to one (IVA) or more (IVB) parts of the body, such as the liver or lung.
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assessment and treatment choices for these patients.
The survival beneﬁt of adjuvant chemotherapy in stage II CRC
remains unproven [4], although the QUASAR study found that
stage II patients treated with chemotherapy had a small but statis-
tically signiﬁcant absolute improvement in survival [5]. For
patients with rectal cancers, preoperative neo-adjuvant chemora-
diotherapy is utilised to decrease local recurrence rates [6],
although such treatment does not compensate for incomplete sur-
gical resection in the form of a positive circumferential resection
margin [7].
Metastasis, a complex and inefﬁcient process that has only
begun to be understood in recent years, is the leading cause of
CRC-related death. Clinicopathological factors are inadequate to
determine the prognosis for patients diagnosed with advanced
CRC, and more than one third of patients will die from progressive
systemic disease. This typically develops through lymphatic vessel
or capillary network intravasation that facilitates spread to nearby
LN and distant organs, respectively or direct invasion of adjacent
structures and transcoelomic spread within the abdominal cavity
after the tumour has penetrated through the intestinal wall.
Although survival has increased from 12 months with 5-FU mono-
therapy to around 24 months with the addition of irinotecan, oxali-
laplatin and targeted drugs, several of the early steps of the
metastatic cascade are not readily targetable in the clinical setting
and drugs that target detectable systemic metastases often do not
work in the adjuvant setting [8]. Furthermore, targeted treatment
with cetuximab, bevacizumab, and panitumumab has had only a
relatively small effect on survival outcomes, partly linked to the
resistance of metastatic CRC to targeted therapy [9].
Improved understanding of the principal molecular networks
associated with CRC is helping with the identiﬁcation of new po-
tential therapeutic agents that target individual pathways with
the prospect of a high degree of biochemical speciﬁcity. Hence, in
future therapies will be selected for an individual patient by
assessment of their tumour and host response for tissue biomark-
ers predictive of disease free 5-year survival [10].
However, response rates for targeted therapy are relatively low
[11] and it is not clear how effective combination-targeted therapyPlease cite this article in press as: S.A. Bustin, J. Murphy, Methods (2012), httpis [12]. Furthermore, these agents frequently have a much broader
speciﬁcity than initially intended, resulting in systemic toxicity
and unexpected side effects [1]. This lack of transparency makes
accurate, preoperative prediction of responsiveness to chemother-
apy challenging. Consequently, treatment decisions are still made
almost exclusively based upon clinicopathological stage at diagno-
sis [13] and chemotherapeutic treatments are administered arbi-
trarily. As a result, this often leads to an ineffective therapy,
delays the administration of a potentially useful drug, causes
avoidable toxicity, encourages the development of resistant CRC
subclones and incurs unnecessary cost.
Personalised medicine promises accurate prediction of an indi-
vidual’s predisposition towards a disease or optimised detection
and management of a patient’s disease in the context of an individ-
ual genetic and environmental proﬁle. Since its realisation in clin-
ical practice depends on the identiﬁcation of safe, effective and
clinically relevant biomarkers for identifying and stratifying pa-
tients [14], relevant biomarkers are the key for individualised adju-
vant treatment. As previously stated, current staging strategies
have difﬁculty with the prospective identiﬁcation of patients with
LN-negative tumours (AJCC stage II) who might beneﬁt from adju-
vant therapy; hence identiﬁcation of molecular staging biomarkers
has long been an area of research priority aimed at the identiﬁca-
tion of diagnostic biomarkers for early detection, prognostic mark-
ers for risk stratiﬁcation and predictive markers associated with
response to a particular therapy [15].2. Biomarkers
Biomarkers are deﬁned as biological substances, characteristics,
or images that provide an indication of the biological state of an
organism [16]. Their proper use requires an understanding of their
sensitivity and speciﬁcity, how and in what contexts to use them
and how to validate them properly [17]. Hence this unassuming
term hides signiﬁcant complexity and can refer to physiological
indicators such as blood pressure, molecular markers such as
expression signatures or radiological biomarkers, such as those de-
rived from computerised tomography or magnetic resonance
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ease, facilitate prognostication or provide a robust understanding
of response to cancer treatment (Fig. 2).
Cancer biomarkers have progressed from biochemical assays
that measure proteins or hormones after the onset of disease to
molecular assays that target disease-speciﬁc nucleic acids and
promise more accurate classiﬁcation, prognosis, risk stratiﬁcation,
treatment efﬁcacy prediction and monitoring. In CRC a wide vari-
ety of biomarkers have been reported within the tumour itself, as
well in blood and faeces, with the genetic proﬁle of the host pro-
viding additional and essential complementary information. In
addition, a range of new biomarkers, termed companion diagnos-
tics, have been described that are designed to provide biological
or clinical information that reﬂects the sensitivity or resistance of
CRC to existing therapies and so aid clinicians in selecting the most
effective therapies [18]. Typically, multigene predictors aim to
stratify the risk of relapse for intermediate-stage CRC after surgical
resection [19]. Gene expression proﬁles of normal colorectal muco-
sa, colorectal adenomas and different stages of CRC have identiﬁed
discriminative expression signatures that mark the tumour pro-
gression sequence [20], providing a reservoir of candidate markers
for the early diagnosis of high-risk colorectal adenomas, as well as
potential therapeutic targets for CRC [21]. Finally, a number of bio-
markers have been proposed as speciﬁc predictors of chemother-
apy, radiotherapy response and, in some instances, drug toxicity
[22].
3. Biomarker location
Since 95% of cases of CRC would beneﬁt from curative surgery if
diagnosis were made at an early stage of disease, early detection of
colorectal adenomas at high-risk of progression to CRC is central to
the aim of reducing CRC deaths. However, current screening meth-
ods are compromised by either low cost-effectiveness or limited
diagnostic accuracy and detect many adenomas that will never
progress to CRC [23]. Hence the importance of ongoing attempts
to identify early diagnostic biomarkers, preferably present in pa-
tient stool or blood thus permitting non-invasive patient assess-
ment. An additional beneﬁt would be the added potential to
detect more synchronous CRCs [24], which may result in additional
surgical procedures and convey a poor prognosis [25]. However, as
of yet no marker has progressed beyond the proof-of-principle and
pilot study stage [26].
3.1. Faeces
Approximately 1.5  106 colonic epithelial cells can be isolated
per gram of stool [27]. Hence faecal analysis constitutes a potentFig. 2. The ﬁgure illustrates the difference between diagnostic, prognostic and predicti
HNPCC) or its presence. The red individual harbours an early stage cancer. (B) Prognostic
risk of disease recurrence by stratifying populations with respect to the risk of disease
biomarkers, which can be either positive or negative, may be a single trait or signature o
given therapy and can themselves be targets for therapy. The black individual will bene
Please cite this article in press as: S.A. Bustin, J. Murphy, Methods (2012), httpand noninvasive method for the detection, monitoring and man-
agement of CRC [28]. However, faeces contain nucleases as well
as intrinsic substances that inhibit many molecular assays, espe-
cially PCR-based tests. Hence the molecular analysis of exfoliated
epithelial cells and RNA-based markers poses a signiﬁcant techni-
cal challenge [29]. RNA is highly labile and is rapidly degraded in
faecal matter. Since most assays require conversion of RNA to
DNA, faecal inhibitors of reverse transcriptases could affect the
accuracy of the results, especially when these depend on quantify-
ing levels of RNA. Nevertheless, there are many reports describing
cancer-associated variation of RNA levels in stool samples. Most
rely on the detection of one or two markers: abnormal expression
of CD44 variants has been reported in the faeces of 60–70% of CRC
patients before surgery, but only in 10–30% of patients after sur-
gery [30]. Detection of cyclooxygenase 2 (COX-2) mRNA on its
own [31], or in combination with matrix metalloproteinase 7
(MMP-7) mRNAs [32] has been proposed for the detection of
CRC, although another report detects COX-2 mRNA in only 50% of
cancer patients [33]. A recent report suggests that patients with
high faecal KIAA0247 mRNA levels have a signiﬁcantly greater 5-
year overall survival rate, and may be associated with therapeutic
beneﬁt following administration of 5-FU [34]. However, it is rather
uncertain whether these results, and those of many other studies
[35], represent real differences in mRNA levels or are artifacts in-
duced by sample preparation, differential RNA stability or inhibi-
tion of either the reverse transcription (RT) or the PCR reactions.
3.2. Blood/plasma
Haematogenous spread of CRC cells from a primary tumour is a
crucial step in the metastasis cascade, and circulating tumour cells
(CTCs) are considered an indicator of tumour aggressiveness [36].
Hence they may provide a potential source of cells for real-time
monitoring of CRC patients through the course of their disease,
enabling the detection of early dissemination of cancers, their
molecular characterisation as well as monitoring treatment re-
sponse or resistance. Consequently, a lot of attention has focused
on the development of assays for their reliable detection and
quantiﬁcation.
Quantitative real-time PCR (qPCR) is the most widely used
method for the detection of CTCs, but the clinical relevance of
the various results reported remains uncertain. This is illustrated
by a report that concludes that CK20 mRNA detection in blood
samples of patients with stage AJCC II CRC identiﬁes individuals
with poor outcome [37]. This conclusion is questionable since
not only is CK20 not expressed in 20% of CRC, but this is associated
with higher grade carcinomas [38] and although that study did not
enrich for epithelial cells, it reported that 174 blood samples fromve biomarkers. (A) Diagnostic biomarkers signal the risk of developing a CRC (e.g.
biomarkers markers may be single traits or a signature of traits used to assess the
outcome in the absence of treatment. Red individuals will relapse. (C) Predictive
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contradicts numerous published results, reviewed in [39], includ-
ing a report that detects CK20 expression in 22% of normal healthy
controls even after immunobead enrichment [40]. Similar contra-
dictory results were obtained in two meta-analyses that used the
same markers (CEA only, CEA and CK20, CK20 only or CK19 and
CK20) as surrogates for circulating tumour cells (CTCs). The ﬁrst
looked at nine studies and concluded that disease-free survival
was signiﬁcantly higher in the CTC negative groups [41]. A second
meta-analysis of 12 different studies concluded that CTC detection
in peripheral blood is not an independent predictor of survival
[42].
Similar contradictions are apparent when more than one or two
markers are used. A recent review of nine studies in patients with
non-metastatic CRC demonstrated that detection rates of CTCs var-
ied from barely detectable to 57%, with seven studies claiming the
presence of CTCs to be a prognostic marker of poor disease-free
survival [43]. But which markers should we use? One study sug-
gests that CEA/CK19/CK20/GCC expression identiﬁes CTCs in CRC
patients with metastatic cancers [44], another that poor survival
is associated with positive detection for CEA/CK20/EGFR [45], with
a third opting for telomerase reverse transcriptase/CK19/CK20/CEA
mRNA expression as an independent predictor for postoperative
relapse [46]. A combination of CEA/CK19/CK20/CD133 levels is
reported to have prognostic signiﬁcance in non-metastatic CRC pa-
tients [47], but that paper does not report any RNA quality assess-
ment data or PCR efﬁciencies and all RT-qPCR data are normalised
against a single unvalidated reference gene. This makes it difﬁcult
to judge whether these results are real or caused by variable RNA
quality or PCR efﬁciencies and even if they are comparable, nor-
malisation of human tissue biopsies against a single unvalidated
reference gene has long been shown to be unreliable [168].
Another report analysing the expression of CEA/CK19/CK20/
CD133/VEGF/EGFR/Survivin found that only CD133 could indepen-
dently predict the survival of these patients [48]. This ﬁnding is
rather surprising, given that CD133 is a marker for haematopoietic
progenitor cells [49] and may or may not be a colorectal stem cell
marker [50].
The most widely quoted evidence for an association between
CTCs and survival comes from a prospective RT-qPCR study that
has demonstrated a signiﬁcant adverse impact on survival with
the presence of P3 CTC per 7.5 ml blood based on selection for
EpCam and detection of CK19, CK20, CEA, or EGFR [51]. These re-
sults are similar to those obtained using a different method, the
immunodetection-based Veridex Cell search system, which also
established a cutoff of P3 CTCs [52] per 7.5 ml blood. However,
it is difﬁcult to compare these methods, since they have different
sensitivities, with the sensitivity of immunodetection reported to
be similar to that of RT-qPCR [53] as well as signiﬁcantly lower
[54]. Furthermore, another study identiﬁed a cutoff of P2 CTCs/
7.5 ml [55], which at the very least suggests that further reﬁne-
ment of cell measurement is required. Finally, a recent meta-anal-
ysis concludes that detection of CTCs in peripheral blood, but not in
mesenteric blood or bone marrow indicates poor prognosis [56].
However, this analysis does not scrutinise experimental protocols,
RNA or assay quality assessments and omits several relevant stud-
ies. Another report identiﬁed 2/346 genes showing signiﬁcantly
elevated transcript levels in peripheral venous blood specimens
of tumour patients when compared to the nonmalignant control
group [57]. Needless to say that neither is used for the detection
of CTCs in any of the above studies.
For the moment, the uncertainty with respect to immunobead
detection, the absence of correlation between the level of CEA
expression in tumour biopsies and that of the serum [58], and
the discordance with respect to which maker to use implies that
it is best to remain unconvinced about the clinical validity of thesePlease cite this article in press as: S.A. Bustin, J. Murphy, Methods (2012), httpdata. There is simply too wide a range of experimental protocols,
criteria for sample selection, poor quality of assay design, RNA
quality control and lack of transparency in reporting data that gen-
erate huge variability in reported results [59,60].
Other RNA targets being proposed as prognostic markers of one
kind or another are EVI2B, ATP2A2, S100B, TM4SF3, and OLFM4 for
postoperative CRC patients with unclear clinical selection criteria
[61], with a subset, S100B, TM4SF3 and OLFM4 reported to corre-
late with liver metastasis [62]. Clearly there is an urgent need for
standardised isolation and analysis techniques [63] as well as an
international consensus on choice of detection method and mark-
ers [64]. Assuming the assays are detecting genuine CTCs, their
clinical relevance must be veriﬁed in large-scale clinical trials
[65] before their incorporation into risk stratiﬁcation and clinical
decision-making processes in the hospital setting [66].3.3. Primary tumour
A new gene expression classiﬁer for improved risk stratiﬁcation
of patients with AJCC stage II CRC, but not stage III, has just been
published [67]. Although the independent prognostic value of the
classiﬁer was conﬁrmed by multivariate analysis, the gene list dif-
fers from all previously published genes and gene lists. This con-
ﬁrms a previous ﬁnding that suggests the overlap of candidate
gene lists associated with speciﬁc clinical/biological phenotypes
remains disturbingly poor between studies [68]. The challenge is
illustrated by a recent review of 23 independent gene expression
proﬁling studies on CRC prognosis that identiﬁed 1475 unique,
mapped genes, of which only 54 genes were reported in at least
two studies and showed consistent direction in expression change
between the single studies [69]. The interpretation and translation
of these studies is impeded by poor experimental protocols, heter-
ogeneous patient populations, unclear signiﬁcance of the genes in-
cluded in each signature, minimal external validation and non-
transparent reporting of protocols and analysis methods [68,70].
Furthermore, the prognostic value of these gene signatures has
not been carefully compared with that of conventional clinical
and pathological risk factors [71].
One of the major limitations with the majority of available data
is the small sample size each study investigates, which can result
in data overﬁtting. This is because the number of markers queried
vastly exceeds the number of patients tested, which may result in a
spurious association between data and outcome, generating a
model that ‘‘ﬁts’’ the data by chance. Hence the choice of appropri-
ate classiﬁcation algorithm is essential for analysing these data and
has led to the development of several classiﬁcation algorithms
[72–74]. Furthermore, the validation of any model requires that
it be tested on a completely independent set of samples. Many
studies struggle to ﬁnd a sample set of appropriate size and com-
parable characteristics. For example, the identiﬁcation of a set of
markers able to distinguish patients with AJCC stage III CRC with
no recurrence from patients with stage IV carcinoma with hepatic
metastasis is based on results from nine and ten patients, respec-
tively [75]. An entirely different-gene prognostic signature was ob-
tained from another comparison of gene expression patterns
between 41 metastatic and non-metastatic stage-matched human
CRCs [76]. A 14-gene signature potentially predicting response to
LV, 5-FU, and irinotecan (FOLFIRI) contains yet another gene list
without any obvious association with biochemical pathways in-
volved in CRC and is based on 21 patients [77]. Two Japanese stud-
ies have published gene signatures that predict responders to
FOLFOX therapy. The ﬁrst study identiﬁed a 21 gene signature,
based on the differential expression between 40 responders and
non-responders [78], the second one published a 14-gene signa-
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is found in the other one.
Another limitation relates to questionable experimental proto-
col standards, with few reports describing adequate RNA quality,
RT or PCR efﬁciency assessments. Furthermore, the restrictions im-
posed by the choice and location of oligonucleotides used in
expression microarray studies have become a potential source of
error since it has become clear that splicing aberrations are charac-
teristic of cancer development [80]. This provides not just a poten-
tial source of candidate biomarkers [81], but also poses problems
for the interpretation of gene expression analyses using micro-
arrays and RT-qPCR. Finally, tumour risk and response to therapy
is not just cancer-dependent, but also associated with host charac-
teristics; hence the importance of a recent report describing a
strong correlation between host immune response and a twelve
immune gene-related signature associated with better patient sur-
vival independent of tumour staging, site, microsatellite instability
or stability, and patient treatment, suggesting some beneﬁcial, in-
tra-tumoural immune cell priming [82].
A study using a combination of RT-qPCR and immunohisto-
chemistry reports that increased expression of MMP2 in primary
tumours is associated with lower overall survival, but fails to pro-
vide any clinical information on the patient group [83]. On the
other hand, higher expression of MMP2, together with that of
MMP 9, 11 and 14 in liver metastases has been reported as
associated with a favourable response to palliative, 5-FU-based
chemotherapy [84]. MMP7 is of particular interest, since its expres-
sion is conﬁned to carcinomatous epithelium and it has been re-
ported as an independent prognostic factor for survival in
advanced CRC [85]. Of the other MMPs investigated, MMP21 may
be an independent prognostic factor in patients with AJCC stage
II as well as stage III CRC [86] and MMP13 has been reported as
associated with postoperative relapse [87].
The value of molecular markers to predict rectal cancer re-
sponse to preoperative chemoradiation is equally unclear [88,89].
Although higher expression of MMP9 alone in epithelium and low-
er expression in stromal cells has been reported as a prognostic
marker for overall survival [90], a recent serial analysis of gene
expression (SAGE) and RT-qPCR analysis has identiﬁed a thir-
teen-gene signature from AJCC stage II/III patients that claims to
predict preoperative chemoradiotherapy response and outcome
in rectal cancers with an overall accuracy of 76% [91]. Again it is
instructive that this gene signature does not include MMP9.
3.4. miRNA
MicroRNAs (miRNAs) are a class of endogenous short (22
nucleotides) noncoding RNAs capable of regulating the expression
of protein-coding genes at the post-transcriptional level by cleav-
ing target mRNAs and/or repressing their translation. They appear
to be remarkably stable and resistant to RNases and have been iso-
lated from stool, sputum, serum and plasma, allowing a wide range
of applications in clinical research. Cancer is associated with
frequent aberrant expression of miRNAs, which are capable of
functioning as oncogenes or tumour suppressors to modulate mul-
tiple oncogenic cellular processes. miRNA expression levels in tu-
mours are increasingly acknowledged as potential prognostic
biomarker for CRC: miRNA expression plays an important role in
CRC development and prognosis, with miRNAs regulating all the
major pathways deregulated in CRC [92]. miRs-135a and 135b reg-
ulate the critical wnt pathway through their downregulation of
APC gene expression, which activates the transcriptional cofactor
function of b-catenin [93].
From a practical point of view miRNAs are very stable in archi-
val material and can be retrieved efﬁciently from samples as old as
28 years [94]. However, as with mRNA-based biomarkers, therePlease cite this article in press as: S.A. Bustin, J. Murphy, Methods (2012), httphave been numerous incomplete and contradictory reports about
their role and until issues of RNA and assay quality assessment,
as well as transparent and complete reporting of experimental de-
tails are resolved, the translatability of these results remains
uncertain [95].
There are many reports suggesting prognostic roles for one or
two biomarkers. Low levels of miR-148a and miR-152 may be
found in advanced stages of disease [96] and downregulated
miR-22 [97], miR375 [98] and miR-143 [99] may predict poor
prognosis, with a signiﬁcant correlation between miR-145 expres-
sion and rectal cancer regression also reported [100]. Conversely,
expression of miRNA-93 may reduce CRC recurrence [101],
whereas elevated miR-21 levels have been found in patients unre-
sponsive to ﬂuorouracil chemotherapy and with poor long-term
survival [102]. High levels of miR-31 may be associated with dis-
tant metastases and let-7a is overexpressed only in metastasis
but not in primary cancer.
Multiple miRNA targets have also been identiﬁed, with a prog-
nostic signature of miR 21,135a, 335, 206 and let-7a proposed for
the detection of the presence of metastases [103], although it only
has a speciﬁcity of 87% and sensitivity of 76%. The presence of a
KRAS mutation is associated with dysregulation of several miRNAs
that target genes involved in apoptosis and proliferation [104]. Fur-
thermore, a colon miRNA signature comprising eleven overexpres-
sed and eight underexpressed miRNAs may be involved in
regulation of stem cell differentiation and thus provide potential
cancer stem cell therapy targets [105].
Relatively little work has been done on the signiﬁcance of circu-
lating miRNA in CRC [106] and there is little consistency in the re-
ported results. miR-17-3p and miR-92a levels may be signiﬁcantly
higher in the plasma and cancer samples of CRC patients, with
plasma levels signiﬁcantly reduced after surgery [107]. Another
study reports that that high levels of miR-221 may be a potential
marker for diagnosis and prognosis of CRC [108]; in contrast a third
study reports that plasma levels of miR-29a and miR-92a, but not
miR-17-3 or miR-221 have diagnostic value [109]. Although an-
other study also found that serum miR-29a levels were signiﬁ-
cantly higher in patients with liver metastases [110], the
sensitivity and speciﬁcity of that assay was only 75%. Yet another
study found that circulating miR-34a levels are reduced in CRC pa-
tients [111].
Unsurprisingly, several studies have attempted to use miRNAs
from faeces as screening and prognostic markers for CRC although,
as is now usual, there is no agreement between the studies. An
analysis of miRNA expression of exfoliated colonocytes identiﬁed
the miR-17-92 cluster and miR-135 as being signiﬁcantly upregu-
lated in CRC tissues compared with normal colon, although the
overall sensitivity and speciﬁcity was only 74.1% and 79.0%,
respectively [112]. In contrast, another study identiﬁed increased
expression of miR-21 and miR-106a in the stool of CRC patients
[113]. Intriguingly they were higher in patients with adenomas
and tended to decrease in cancer. Another study suggested
down-regulation of fecal miR-143 and miR-145 as potential mark-
ers for CRC [114].
miRNAs also have potential therapeutic applications, since
synthetic oligonucleotide antagomirs that inhibit overexpressed
miRNA such as miR-135 can result in an increased expression of
APC in CRC cell cultures and miRNA mimics can compensate for
downregulated miRNAs such as miR-143 and miR-145, leading to
decreased cancer cell proliferation in vitro [92].4. Practical limitations
The excitement about biomarkers originating from research
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[115]. As has become clear, many of the studies reporting the dis-
covery of biomarkers useful for CRC management are retrospec-
tive, involve small series of patients and are unable to predict
disease progression accurately with clinically adequate resolution
and reproducibility [116]. Sample size is important as small stud-
ies can give inﬂated, over-promising results as a result of selec-
tion bias [117]. While small study populations are likely to be
more homogeneous and thus molecular classiﬁers may be more
efﬁcient, they are frequently underpowered and thus unable to
discriminate informative molecular signatures and may incor-
rectly reach negative conclusions. Study endpoints are an addi-
tional critical aspect of oncologic clinical trials that require
careful attention when assessing the relevance of biomarkers
and the efﬁcacy of treatment [118]. As a consequence, although
a combinatorial approach to molecular prognostics, similar to
the that established for breast cancer patients, may have signiﬁ-
cance and be used in future for CRC patient management [119],
currently research has failed to yield consistent sets of externally
validated markers [120] that clinicians could use for clinical deci-
sion making [121].
Even when concerted efforts are made to minimise the num-
ber of variables, the data themselves are so vast that they can
contribute signiﬁcant background noise. Clearly, it is essential
to combine and integrate molecular data with other sources of
genomic, proteomic, biomedical and clinical data from patient
records.
The ﬁndings of many studies are contradictory and the cur-
rent reality is that a single genetic marker, KRAS gene, has made
the transition into clinical practice in the case of EGFR-targeted
therapy for metastatic disease [122]. Disconcertingly, even
though current evidence and expert consensus does not support
the clinical validity of RNA-based biomarkers, there are commer-
cial tests that appear to be marketed as useful assays supporting
the clinical decision-making process for individual cancer pa-
tients [15]. So although both the Oncotype DX Colon and Colo-
Print gene signatures may provide prognostic information
about risk of recurrence, neither assay has demonstrated the
ability to predict which patients will beneﬁt from adjuvant che-
motherapy, a primary goal of personalised oncological medicine
[4].
Finally, there is another important, rarely publicised reason for
the observed discrepancies among peer-reviewed publications.
Recent years have seen a signiﬁcant increase in the number of re-
tracted publications, many reporting the use of molecular tech-
niques to link expression signatures, clinicopathological features
and individualised therapy in various cancers, including CRC. The
most common reason for these retractions is error [123,124] and
deliberate fraud [125]. These retractions are complemented by
numerous corrections that are frequently sufﬁciently extensive
to warrant a retraction as well as rebuttals that point out mistakes
in publications. Furthermore, the frequency of retraction shows a
strong correlation with the journal impact factor [126]. Worry-
ingly, rebuttals have no effect on the number of times that publi-
cation is cited, and even then the citing papers on average have
neutral views of the original article, or believe that the rebuttal
agreed with it [127]. As a result, the peer-reviewed literature is
plagued by contradictory, irrelevant, wrong or fraudulent publica-
tions that combine to pose a challenge to the integrity of the sci-
entiﬁc literature, with serious consequences not just for basic
research, but potentially calamitous implications for drug develop-
ment and disease monitoring [128]. Indeed, this problem is abun-
dantly clear to any reader of the literature concerning molecular
biomarkers, as has been referred to repeatedly in the course of this
review.Please cite this article in press as: S.A. Bustin, J. Murphy, Methods (2012), http4.1. Biological variability
The biological variability that is characteristic of human beings
introduces an important confounding issue into the identiﬁcation
of universal molecular biomarkers:
 Colorectal tissue consists of individual cells from a variety of
lineages that reside in a changeable natural environment and
interact as coordinated and dynamic partners.
 Genetic and epigenetic differences generate unpredictable and
unique genomic backgrounds.
 The internal environment of each cell is highly stochastic with
constantly changing concentrations of metabolites, RNA, regu-
latory molecules and proteins [129].
This results in signiﬁcant differences in gene expression pat-
terns between individual cells [130] that create variable behaviour
patterns [131] and must not be ignored [132]. It must also be
remembered that CRC biopsies are composed of epithelial cells as
well as numerous other cell types. Variable proportions of these
non-epithelial and non-malignant cells could lead to inconsistent
and biologically inaccurate gene expression patterns. Although
analysis of microdissected cell populations partly addresses these
problems [133], this creates its own disadvantages: a signiﬁcant
proportion of metastasis-associated signatures appear to be de-
rived from the nonepithelial component of the tumour and micro-
dissection would result in the loss of that component [134]. The
case for considering expression proﬁles of both epithelial and stro-
mal cells is further strengthened by strong evidence that the inter-
action between malignant cells and (myo)-ﬁbroblasts [135] as well
as macrophages [136] in the tumour microenvironment modulates
the biological behaviour of CRC All these factors may generate
noise that could mask expression patterns relevant for outcome
prediction.
Data interpretation following expression proﬁling experiments
is further complicated by our patchy understanding of the com-
plexity of biological systems, illustrated by wide baseline variabil-
ity of RNA levels in individual cells and tissues due to normal
in vivo degradation [39], transcript splicing that affects most hu-
man genes [137] and plays an important role in cancer pathology
[138], differences in allelic expression among autosomal non-im-
printed genes in animals [139], the discovery of novel RNA species
[140] and new ﬁndings in relation to the regulatory roles of RNA
[141]. Appropriate biological replication is essential if data are to
be valid in the context of a large population from which the sub-
jects were sampled, rather than only for the particular individuals
considered in the experiment [142]. Since biological variability is
larger than technical variation, increasing biological replication
usually translates into more effective gains in power. However,
increasing sample size generally leads to increased cost and time
requirements to perform the experiments. In addition, some bio-
logical replication cannot be increased, e.g. when comparing large
numbers of healthy individuals with a limited number of patients
with a particular disease. Clearly, biologically relevant data inter-
pretation requires the development of dedicated experimental pro-
tocols and analytical procedures [143] as well as incorporation into
more realistic statistical models to allow biologically relevant data
interpretation [144]. One consequence of this is the need for move-
ment towards a quantitative description of complex biological sys-
tems involving the interaction of many components, rather than a
narrow focus on a description of single biomolecules or even path-
ways and their interaction with other individual molecules or
pathways.
Finally, host genetics plays a critical and increasingly recognised
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20 October 2012to adjuvant therapies. In practice this means that malignancy is
inﬂuenced not just by environmental stimuli, or multiple genetic
and epigenetic events that arise within the malignant epithelium,
but also by the genetic background of the host [145]. In addition,
there is an important contribution from the tumour microenviron-
ment and metastasis can be modiﬁed by stromal events. Conse-
quently it is plausible that multiple signatures could be a
consequence of the multiple pathways through which CRC metas-
tases arise [146], as demonstrated by the fact that LN and liver
metastases from the same patient do not always show the same
genetic aberrations [147]. This implies that the accuracy of multi-
genic classiﬁers might be improved if their selection were based on
better understanding of the underlying tumour biology. The ﬁnd-
ing of a molecular signature in primary cancers predictive of
metastasis [134] suggests that the metastatic potential of many
cancers is encoded in the bulk of the primary tumour and raises
the expectation that this will result in a prognostic application.
Nonetheless, it is notable that CRCs were not included in the
demonstration of clinical utility for their metastasis-associated
signature, although another study does describe such a signature
for AJCC stage III CRC patients [148]. Interestingly, this study also
suggests that detection of the expression of a single mRNA, the
RAS homologue RHOA, can identify a subset of patients that may
beneﬁt from adjuvant chemotherapy. However, this depended on
selecting appropriate thresholds for mRNA levels, with the associ-
ated problems this entails [59].
4.2. Technical variability
A second major cause for the scarce translation of molecular
biomarkers into clinical practice is not just a lack of quantitative
techniques [122], but an immense technical variability that derives
from sampling, assay design and measurement errors that results
in a lack of deﬁnition, adequate validation, and hence easy imple-
mentation of quantitative data [121]. This is readily illustrated by a
recent report demonstrating that the use of formalin-ﬁxed, paraf-
ﬁn-embedded samples to classify CRCs according to their methyl-
ation status generates unsatisfactory and non reproducible
bisulﬁte conversions leading to random results for methylation
levels [149].
4.2.1. Microarrays
There are several technical limitations that have the potential to
introduce uncertainty into the reliability of DNA microarray
measurements and whilst the Minimum Information About a
Microarray Experiment (MIAME) guidelines [150] describe the
minimum information required to enable microarray data inter-
pretation and independent veriﬁcation, they do not endorse tech-
nical standards. Consequently, microarray experiments continue
to be characterised by numerous potential liabilities: hybridisation
conditions for different genes are variable [151], misinterpretation
of gene expression data that occurs when RNA quantities are inap-
propriately normalised [152], inappropriate control samples that
limit the validity of the results [153] and limitations of analysis
programs [154]. As a result accurate measurements of expression
levels and the reliable detection of low abundance genes continue
to represent signiﬁcant challenges for microarray technology.
Hence, whilst the direction of change indicated by microarray
experiments may be consistent, the magnitude of gene expression
changes is much less reliable [68] This is one reason why RT-qPCR-
based high throughput massively parallel quantiﬁcation systems,
as well as next generation sequencing systems are likely to sup-
plant microarrays for truly quantitative measurements (but see
below).
Furthermore, there is little consistency between studies used to
predict clinical outcome [155]. This was demonstrated by the lackPlease cite this article in press as: S.A. Bustin, J. Murphy, Methods (2012), httpof association between the expression proﬁles of several cell cycle
regulatory or proliferation-related markers previously correlated
with prognostic relevance and disease-free survival in LN-negative
rectal cancers treated by surgery alone [156]. It is apparent that
single microarray data are prone to false results [157] and that dif-
ferent studies result in different gene lists; indeed different gene-
selection methods can lead to strikingly different gene lists from
the same experiment [158]. It is hoped that the establishment of
gene co-expression networks for functionally related genes will
improve the biological validity of microarray data, exempliﬁed by
a study that combined independent datasets on different types of
cancer to explore transcriptional changes in terms of gene interac-
tions rather than at the level of individual genes [159]. Two distinct
networks were able to detect biological changes and identify gene
groups whose co-regulation might contribute to malignant
transformation.4.2.2. RT-qPCR
RT-qPCR technology provides a textbook example of the techni-
cal problems associated with technologies commonly assumed to
be mature by clinicians, but which are actually full of technical pit-
falls. The ubiquity of RT-qPCR has resulted in an abundance of pro-
tocols that differ at every stage of the experimental workﬂow and
provide ample scope for the introduction of inconsistencies that
are responsible for the many contradictory results reported in
the scientiﬁc literature. Discrepancies are further magniﬁed by
experiment- and individual-speciﬁc variation, since even though
tissues or targets may be seemingly the same, experimental sam-
ples, protocols and data analysis methods inevitably differ. Other
inconsistencies arise because the investigator has a choice of dis-
tinct instruments, a wide range of enzymes that are further
adapted by manufacturer-speciﬁc reaction buffers and data analy-
sis software based on different statistical methodology [128].
Poor experimental design is inherently associated with techni-
cal variability: inappropriate underlying assumptions generate re-
sults that may be biologically or clinically of little consequence and
have negligible translational relevance [160]. This source of vari-
ability is prompted by experimental designs employing false
assumptions, deﬁcient technologies, inappropriate sampling pro-
cedures, inconsistent use of controls, incorrect methods of normal-
isation, unsound data analysis procedures and misdirected
statistical methodologies [161]. As discussed earlier, there are
numerous instances of publications reporting one observation
and being contradicted by others reporting opposite results,
impeding the translation of qPCR technology into clinical practice.
The key to minimising variability is careful attention to [162] as
well as assiduous reporting of [128] experimental detail. Regretta-
bly, the vast majority of publications do not provide sufﬁcient
information to allow the reader to infer whether published data
support the conclusions of the publications [163]. In principle, gi-
ven sufﬁciently comprehensive information, any reader comparing
discordant published results should be able to discern which ones
are likely to be caused by ﬂaws in experimental design, execution
or interpretation. In practice, this essential detail is usually not
available and detailed examination of discordant data is either
not possible or requires the investment of an inordinate amount
of effort. The growing consensus around the need to improve
published information with relevant experimental detail, as well
as issues relating to pre- and post-assay parameters has resulted
in the publication of the ‘‘Minimum Information for Publication
of Quantitative Real-Time PCR Experiments’’ (MIQE) guidelines
[164], with a recent amendment clarifying the disclosure of primer
sequences [165]. The last year has seen a rapid adoption of these
guidelines and their implementation by clinical researchers should
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20 October 2012and reporting principles and so contribute to the publication of
more clinically relevant, and hence translatable results.
5. Conclusions and outlook
CRC arises from complex, variable and patient-speciﬁc interac-
tions between genetic, epigenetic and environmental factors
(Fig. 3). The development, improvement and increased sophistica-
tion of a wide range of molecular tools has accelerated the transi-
tion to large-scale systemic approaches for the study of this
disease, making it possible to analyse the expression patterns asso-
ciated with its molecular pathogenesis. As a consequence, the last
20 years have witnessed a remarkable increase in knowledge of the
CRC transcriptome. The identiﬁcation of critical molecular path-
ways associated with CRC tumourigenesis and metastasis has dem-
onstrated the feasibility of achieving better outcome prediction by
combining large-scale molecular analyses with classic morpho-
logic and clinical methods of staging and grading cancer. This is
driving the pursuit for a change of emphasis of tumour classiﬁca-
tion from morphological to molecular markers and has led to the
identiﬁcation of numerous potential prognostic biomarkers.
Nevertheless, although numerous individual markers and
several expression proﬁles have been reported as independent
predictors of disease outcome, none have been universally
validated and they have not yet been adopted into routine clinical
decision-making [10]. Studies often generate vast amounts of infor-
mation without any clear evidence that this is any more relevant
than available strategies for practical patient management. Hence,
despite the introduction of targeted drugs for the treatment of
advanced CRC and improved overall survival for non-resectableFig. 3. CRC tumourigenesis. Progression from normal epithelium through adenoma an
miRNAs (purple and green) and mRNAs (blue and red) affecting key signalling p
Carcinogenesis progresses by several pathways, usually characterised by early acquisitio
frequent activating mutations of the KRAS oncogene and inactivating TP53 mutations. O
Please cite this article in press as: S.A. Bustin, J. Murphy, Methods (2012), httpdisease, cure rates remain low. Currently KRAS is the only sufﬁ-
ciently validated predictive molecular marker for anti-EGFR direc-
ted therapy, with the predictive value of BRAF mutations still
unclear. Even so, there are currently no US Food and Drug Adminis-
tration-approved assays for the detection of KRAS mutations [166].
There are numerous studies underway aimed at incorporating
putative predictive molecular markers into the clinical decision
making process, and it seems safe to suggest that the use of molec-
ular markers in routine clinical practice will increase as more
markers are identiﬁed and validated. Furthermore, technical pro-
gress continues apace, with 2012 witnessing the introduction of
new sequencings instruments that enable a whole human genome
to be sequenced at a run cost of $1000. Together with the identiﬁ-
cation of new, selective inhibitors of the signalling pathways criti-
cal to CRC and the development of innovative technologies for the
simultaneous detection of biomarkers and therapeutic drugs, this
will lead to the enhanced potential for targeted disease manage-
ment in the individual patient.
However, a lot remains to be done. There are numerous techni-
cal issues that need to be addressed, not least the need to develop a
range of software tools to incorporate patients’ genomic informa-
tion into the clinical decision making process. It is essential that
technical variability is minimised by using operating procedures
that implement rigorous standards at each step of a study, espe-
cially with regard to careful experimental quality control with
associated quality metrics [167]. This is of particular importance
where studies aim to correlate particular clinical outcomes with
mRNA or miRNA expression proﬁles changes. Extensive validation
of expression proﬁles on external sets is essential and it is impor-
tant that clinical studies are more carefully designed with stringentd CRC to metastasis is characterised by accumulated abnormalities of individual
athways. ECM (extracellular matrix), EMT (epithelial-mesenchymal transition).
n of APC mutations that lead to deregulated wnt signalling. Some tumours harbour
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20 October 2012criteria for assigning outcomes to samples. There is no substitute
for disease-free survival; hence these clinical studies are likely to
involve long-term prospective trials in order to determine whether
expression-based cancer proﬁling is equal to, or better than con-
ventional methods. Finally, we would like to remind researchers
and clinicians alike that every new molecular technique shows tre-
mendous promise until subjected to the rigorous evaluation of
real-life clinical diagnostics.
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